Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting
Pittsboro, NC — November 11, 2024
Xyzagen’s neurology focused drug development and research team, is proud to announce it’ll be presenting a poster on new Kv7 channel opener chemistry. This presentation will take place at the upcoming American Epilepsy Society (AES) Annual Meeting 2024, December 6-10 in Los Angeles, California.
“New Kv7 Channel Opener Chemistry for Treatment of Seizures,”
will be presented at poster session 1.396 on Saturday, December 7, 2024, from 12-2pm.
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.
Our knowledge in pharmacology/pharmacogenomics and in vitro/in vivo pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients and CROs to work directly with experts.



